Combinatorial treatment options for highly resistant compound mutations in the kinase domain of the BCR::ABL1 fusion gene in Ph-positive leukemias

Am J Hematol. 2024 Jan;99(1):E9-E11. doi: 10.1002/ajh.27095. Epub 2023 Dec 12.
No abstract available

Publication types

  • Letter

MeSH terms

  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate
  • Leukemia*
  • Mutation
  • Protein Kinase Inhibitors / pharmacology
  • Protein Kinase Inhibitors / therapeutic use

Substances

  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Protein Kinase Inhibitors